"From Injections to Diet..." Hanmi Pharmaceutical Launches EpiDay Obesity Management App
Integrated tracking of injections, meals, exercise and body composition
Offers AI health coaching and a dashboard for healthcare professionals
Hanmi Pharmaceutical said on Nov. 6 that it had launched EpiDay, a digital obesity management solution app that helps users record and manage everyday health data, from injections and meals to exercise, body composition and physical condition, and share it with healthcare professionals.
EpiDay focuses on connecting health records patients build up outside the clinic with healthcare professionals to create a more continuous obesity management environment.
The patient app offers a range of features needed for obesity management, including injection records and schedule management, meal and exercise tracking, weight, body composition and physical condition logs, AI health coaching, and hospital matching. Users can record not only injection schedule reminders but also dosage, injection site and past injection history.
When users take a photo of their food, AI analyzes its nutritional information. They can also continuously log changes in their weight, body composition and physical condition to monitor their health. The app also provides body composition and exercise management features, including automatic syncing of InBody data.
Through a patient-specific dashboard, healthcare professionals can view key data at a glance, including changes in weight and BMI, injection history, diet and physical condition. The app also provides reports summarizing patients' recent health changes, enabling healthcare professionals to assess more efficiently how a patient's condition has changed between outpatient visits.
The system for healthcare professionals also provides access to key clinical and product materials related to obesity treatment, as well as information on how to administer injections, patient education and counseling materials, guides to operating obesity clinics, and materials on body composition measurement devices such as InBody and DEXA.
Hanmi Pharmaceutical is continuing development with the goal of launching the world's first digital combination drug in 2028. It also plans to incorporate clinical decision support system (CDSS) features in the future to support healthcare professionals in reviewing dosages based on information entered into the system, including patients' medication histories and treatment progress.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
"Through EpiDay, which combines Hanmi's expertise in obesity and metabolic diseases with digital technology, we aim to create an environment in which obesity management continues outside the clinic. We will expand into digital combination drugs in the future and present a new model for obesity management," said Kim Nayoung, vice president of Hanmi Pharmaceutical's Innovation and Growth Division.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.